Category-Defining Platform for Engineered Healthspan
$20M Series A at $60M Pre-Money | Q1 2025
Executive Summary
The Opportunity
The $600B+ longevity market is growing 15% annually with zero category-defining leaders. Practitioners currently stack supplements and compounds without framework or sequencing logic, leading to suboptimal outcomes and patient frustration.
The Solution
We formalized the Bio-Energetic Sequencing Model - the first dependency-gated framework proving that indefinite biological age reversal is achievable through systematic cellular optimization.
The Breakthrough
- Mathematical proof of indefinite healthspan extension
- 74 scientific sources validating dependency-gated mechanisms
- 5-phase clinical protocol (286 pages) with biomarkers
- 3 published papers establishing scientific credibility
- Strategic global deployment framework complete
The Ask
$20M Series A at $60M pre-money to execute clinical validation, build practitioner platform, navigate regulatory pathways, and establish category leadership before competition emerges. 24-month runway to Series B inflection.
Market Opportunity
$600B+ global longevity market with zero category-defining leaders. First-mover advantage in a greenfield category.
Market Pain Point
Fragmented, ad hoc approach to aging intervention. Suboptimal outcomes, practitioner confusion, patient attrition.
Root Cause
No systematic framework for intervention sequencing. The coordination problem has been invisible until now.
Defensible Moat
First mover defining "engineered healthspan" category. Proprietary IP, published research, network effects from practitioner ecosystem.
Competitive Landscape
Zero category leaders. Incumbents (supplement cos, peptide clinics) lack scientific rigor. No formalized dependency-gated framework exists.
The Bio-Energetic Sequencing Model
Each phase prepares the cellular environment for the next. The sequence matters more than the compounds.
Energy Foundation (NAD+ Restoration)
Restore cellular energy to 70%+ of youthful levels. Without energy, subsequent interventions fail.
Cellular Cleanup (Autophagy Activation)
Activate cellular recycling and waste removal. Requires Phase 1 energy to function properly.
Damage Removal (Senolytic Clearance)
Clear senescent cells creating inflammatory environment. Unprepared tissue can't handle clearance burden.
Regeneration (Stem Cell Support)
Activate tissue regeneration in cleared environment. Requires clean terrain from Phases 1-3.
Maintenance (Continuous Optimization)
Maintain damage below pathological thresholds indefinitely. Decouples biological age from chronological time.
Business Model
Four revenue streams targeting $145M ARR by Year 5 with 70%+ gross margins
B2B Practitioner Platform
$70M ARR- Annual certification: $2,500/practitioner (48% of ARR)
- Protocol access & updates: $1,200/yr/seat
- Biomarker SaaS: $500/mo (85% gross margin)
- Target: 10,000 certified practitioners by Year 3
B2C Protocol Access
$40M ARR- Premium subscriptions: $149â$499/mo (28% of ARR)
- Biomarker testing partnerships: Rev share
- Supplement/intervention coordination: Affiliate
- Target: 50,000 active subscribers by Year 3
IP Licensing
$20M ARR- Enterprise licenses: $500Kâ$2M ACV per institution
- Insurance partnerships: Rev share models
- International expansion: Territory licensing
Clinical Validation Services
$15M ARR- Clinical trial design consulting
- Biomarker interpretation services
- Protocol customization (90%+ gross margin)
Use of Funds ($20M Series A)
Clinical Validation
Phase I safety studies, Phase II efficacy trials, biomarker validation, publication
Platform Development
Practitioner certification platform, patient protocol app, biomarker AI, infrastructure
Regulatory Pathway
FDA/regulatory consulting, clinical documentation, safety monitoring, legal & compliance
Category Leadership
Thought leadership content, medical education programs, conference presence, PR & media
Team Expansion
Chief Scientific Officer, Chief Technology Officer, Clinical Operations Director, Regulatory Affairs
Vision & Milestones
Clear path to category leadership
Foundation
- $20M Series A close
- Core team hired (CSO, CTO, COO)
- Phase I safety studies initiated
- Practitioner platform beta launch
- 1,000 certified practitioners
Validation
- Phase II efficacy results published
- FDA Breakthrough Therapy Designation pursued
- Platform v2.0 with AI biomarker engine
- 5,000 certified practitioners
Scale
- 10,000 certified practitioners
- Major institutional partnerships
- Insurance reimbursement pathways
- International expansion (EU, APAC)
Category Leadership
- Recognized global standard of care
- "Bio-Energetic Sequencing" becomes de facto protocol
- Series B at $500M+ or strategic M&A options
Team
Mullo Saint
Founder & CEO
- Independent researcher who formalized dependency-gated mechanisms in aging
- Developed Bio-Energetic Sequencing Model with 74-source peer-reviewed validation
- Author of 3 published papers establishing scientific credibility
- Created 286-page clinical protocol demonstrating regulatory-ready implementation
- Vision: Decoupling biological age from chronological time at scale
Key Hires (Q1âQ2 Post-Close)
- Chief Scientific Officer: PhD + 10+ years longevity/geroscience research
- Chief Technology Officer: Platform architecture, healthcare SaaS expertise
- VP Clinical Operations: FDA IND experience, trial execution
- VP Regulatory Affairs: 510(k) and Breakthrough Therapy pathway expertise
- Head of Business Development: Institutional partnerships, licensing
Partner With Us to Define the Category
$20M Series A at $60M pre-money to establish category leadership in a $600B+ market